TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mental health gains
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent differences between successive RR intervals > 50 ms (pNN50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute and normalized high frequency power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Control of bias
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall quality scores
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wexner score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal manometry parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative defecating difficulties while squatting
Endpoint domain: Adverse events/effects
Primary endpoint: delayed enhancement in the LV myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for antihypertensive treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for readmission to the obstetrical recovery room
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nasal airflow values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MSNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Crown discoloration
Endpoint domain: Adverse events/effects
Primary endpoint: Periapical repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in facial temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUC(0-t) of lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of chenodeoxycholic acid synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in pool size of deoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of total chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of pharmaceutical care issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airflow obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Depressive Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain score of injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of digital anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Self-reported urge to eat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Binge-eating episodes
Endpoint domain: Life impact
Endpoint subdomain: Eating behavior
Primary endpoint: Improvement in total IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postvoid residual volume higher than 300 mL
Endpoint domain: Adverse events/effects
Primary endpoint: Peak flow rates below 5 mL/s
Endpoint domain: Adverse events/effects
Primary endpoint: Suppression of P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systolic blood pressure (sBP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent dyspnea or functional limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma malondialdehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of reduced glutathione to oxidised glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary nitrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint-motion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily life activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TCRVbeta7 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBV-DNA negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBeAg negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median amount of cancer in needle biopsy sets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of adenocarcinomas with Gleason score of 7 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of adenocarcinomas with adverse prognostic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: tolerability of itraconazole compared to griseofulvin
Endpoint domain: Adverse events/effects
Primary endpoint: m-YPAS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative favorable outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in scar volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of activated partial thromboplastin time (aPTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Factor IX inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Heel pad stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patency of the infarct-related artery (TIMI grade 2 or 3 flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality rate at 6 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Time to reach the cut-off for reducing peri- and post-operative risk of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delayed any type of sexual initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduced unprotected sex at last intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increased number of recent vaginal sex partners
Endpoint domain: Adverse events/effects
Primary endpoint: Strokes
Endpoint domain: Mortality/survival
Primary endpoint: Least angular deviation of proximal grooves from path of insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urethral pressure variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: static urethral pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: self-reported interface-related pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost of sight impairment
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Standardized mean difference between sham acupuncture and no acupuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venoconstrictor response to noradrenaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability in pressure readings (coefficient of variation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent with pressure readings ≥18 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-tidal CO2 at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to neuromuscular blockade onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: force required to dislodge posts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complete abortion
Endpoint domain: Mortality/survival
Primary endpoint: Rate of acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hemofilter life-span
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rebleeding risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decompensation of cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid artery intimal medial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self‐recorded neck pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain medication dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean duration of >60% rigidity of the base of the penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of >60% rigidity at the tip of the penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rigidity activity units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early asthmatic response (EAR) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Late asthmatic response incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal severity of bronchial response (FEV1 decrease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Medication adherence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of biopsy-confirmed acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in arch drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in AHI sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in AHI standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean hemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Comfort, satisfaction, and tolerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean difference in estimated vs measured CER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of estimated CER within 30% of measured CER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of estimated CER within 15% of measured CER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reading performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vergence facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever incidence (> or =38.1 degrees C)
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity (serum‐neutralizing antibody titer rise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient ratings of the alliance and technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body Mass Index (BMI) accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure (BP) self-measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MHQ total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Score of AR symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of physical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in colony-forming units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noradrenaline excretion in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-back symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of high-grade cervical intraepithelial neoplasia (CIN 2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of time the oesophageal pH < 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of time the oesophageal pH < 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Worsening of reflux oesophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: N45 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: N100 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: global mean field amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Apnea-Hypoxia Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between hyoid bone to retrognathia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between hyoid bone and mandibular plane angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron metabolism improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythrocyte generation promotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: elevation in mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction in body image distortion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer lateral drifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer unsignaled lane changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: more time spent following at close distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of goals achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic evidence of filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean increased amount of attached gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum values of CK (MB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum values of troponin-T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum values of troponin-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local and widespread pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: snack consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in GAPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cumulative proportion of thrombosis-free individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reaction frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Neopterin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in symptom scores at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bronchodilator use at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in treadmill exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scale reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aided recognition for trained materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived involvement in GP decision making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likelihood of regaining pre-exacerbation FEV1 by discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in symptom severity at discharge
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Major coronary event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Any CHD event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Any revascularization procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: maximal exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: other mortality
Endpoint domain: Mortality/survival
Primary endpoint: Intrahepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum plasma concentration (t max) of both enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biochemical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders with at least a 25% MOSES irritability/aggressiveness subscore decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MOSES irritability/aggressiveness subscores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with at least one extrapyramidal symptom
Endpoint domain: Adverse events/effects
Primary endpoint: Patient experience of VA care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver experience of VA care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean weekly DPN pain at endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition to psychosis within 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Time from symptom onset to hospital presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental costs of DBT vs. DM
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 60-day rates of death, rehospitalization, or unscheduled medical visits
Endpoint domain: Mortality/survival
Primary endpoint: Triglyceridemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensory dysfunction of the skin in the operated groin
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic postoperative pain
Endpoint domain: Adverse events/effects
Primary endpoint: superior-inferior respiratory tumor motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall respiratory tumor motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: amount of postoperative pain medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: shoot elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leaf number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal confirmed hypoglycaemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: mean area under the plasma concentration‐time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of treatment‐emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Need for rescue antiemetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes